PIA
KDNY

Piedmont Investment Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Piedmont Investment Advisors’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-223
Closed -$8K – 2484
2018
Q2 		$8K Buy
+223
New +$8.55K ﹤0.01% 1940

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Piedmont Investment Advisors's KDNY Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2018, closing a stake of 223 shares — an estimated $8K sold.

Piedmont Investment Advisors first reported a position in KDNY in Q2 2018 and held it in 1 quarter. The position peaked at $8K in Q2 2018. 87 funds tracked by Wall St. Rank hold KDNY as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 223 Chinook Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $8K.
  • Piedmont Investment Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $8K in Q2 2018.
  • 87 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.